Literature DB >> 21889565

How porphyrinogenic drugs modeling acute porphyria impair the hormonal status that regulates glucose metabolism. Their relevance in the onset of this disease.

Laura B Matkovic1, Florencia D'Andrea, Daiana Fornes, Leonor C San Martín de Viale, Marta B Mazzetti.   

Abstract

This work deals with the study of how porphyrinogenic drugs modeling acute porphyrias interfere with the status of carbohydrate-regulating hormones in relation to key glucose enzymes and to porphyria, considering that glucose modulates the development of the disease. Female Wistar rats were treated with 2-allyl-2-isopropylacetamide (AIA) and 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) using different doses of AIA (100, 250 and 500mg/kg body weight) and a single dose of DDC (50mg DDC/kg body weight). Rats were sacrificed 16h after AIA/DDC administration. In the group treated with the highest dose of AIA (group H), hepatic 5-aminolevulinic acid synthase (ALA-S) increased more than 300%, phosphoenolpyruvate carboxykinase (PEPCK) and glycogen phosphorylase (GP) activities were 43% and 46% lower than the controls, respectively, plasmatic insulin levels exceeded normal values by 617%, and plasmatic glucocorticoids (GC) decreased 20%. GC results are related to a decrease in corticosterone (CORT) adrenal production (33%) and a significant reduction in its metabolization by UDP-glucuronosyltransferase (UGT) (62%). Adrenocorticotropic hormone (ACTH) stimulated adrenal production 3-fold and drugs did not alter this process. Thus, porphyria-inducing drugs AIA and DDC dramatically altered the status of hormones that regulate carbohydrate metabolism increasing insulin levels and reducing GC production, metabolization and plasmatic levels. In this acute porphyria model, gluconeogenic and glycogenolytic blockages caused by PEPCK and GP depressed activities, respectively, would be mainly a consequence of the negative regulatory action of insulin on these enzymes. GC could also contribute to PEPCK blockage both because they were depressed by the treatment and because they are positive effectors on PEPCK. These disturbances in carbohydrates and their regulation, through ALA-S de-repression, would enhance the porphyria state promoted by the drugs on heme synthesis and destruction. This might be the mechanism underlying the "glucose effect" observed in hepatic porphyrias. The statistical correlation study performed showed association between all the variables studied and reinforce these conclusions.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21889565     DOI: 10.1016/j.tox.2011.08.014

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  6 in total

1.  Melatonin modulates drug-induced acute porphyria.

Authors:  Sandra M Lelli; Marta B Mazzetti; Leonor C San Martín de Viale
Journal:  Toxicol Rep       Date:  2016-01-07

Review 2.  Nutrients and Porphyria: An Intriguing Crosstalk.

Authors:  Elena Di Pierro; Francesca Granata
Journal:  Int J Mol Sci       Date:  2020-05-14       Impact factor: 5.923

Review 3.  Therapy Follows Diagnosis: Old and New Approaches for the Treatment of Acute Porphyrias, What We Know and What We Should Know.

Authors:  Petro E Petrides
Journal:  Diagnostics (Basel)       Date:  2022-07-03

4.  Hepatic Transcriptome Responses in Mice (Mus musculus) Exposed to the Nafion Membrane and Its Combustion Products.

Authors:  Mingbao Feng; Ruijuan Qu; Mussie Habteselassie; Jun Wu; Shaogui Yang; Ping Sun; Qingguo Huang; Zunyao Wang
Journal:  PLoS One       Date:  2015-06-09       Impact factor: 3.240

5.  High Prevalence of Insulin Resistance in Asymptomatic Patients with Acute Intermittent Porphyria and Liver-Targeted Insulin as a Novel Therapeutic Approach.

Authors:  Isabel Solares; Laura Izquierdo-Sánchez; Montserrat Morales-Conejo; Daniel Jericó; Francisco Javier Castelbón; Karol Marcela Córdoba; Ana Sampedro; Carlos Lumbreras; María Jesús Moreno-Aliaga; Rafael Enríquez de Salamanca; Pedro Berraondo; Antonio Fontanellas
Journal:  Biomedicines       Date:  2021-03-05

Review 6.  Cutting-Edge Therapies and Novel Strategies for Acute Intermittent Porphyria: Step-by-Step towards the Solution.

Authors:  Miriam Longo; Erika Paolini; Marica Meroni; Paola Dongiovanni
Journal:  Biomedicines       Date:  2022-03-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.